Compare Smurfit WestRock plc Ordinary Shares (SW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smurfit WestRock plc Ordinary Shares vs Tango Therapeutics Inc. — how do they compare? Smurfit WestRock plc Ordinary Shares trades at $41.19 (market cap $21.74B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Smurfit WestRock plc Ordinary Shares is far larger — about 5.8× Tango Therapeutics Inc.'s market cap, and Smurfit WestRock plc Ordinary Shares pays a 4.36% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smurfit WestRock plc Ordinary Shares for 5 Days and Tango Therapeutics Inc. for 0 Days on average.
| SW | TNGX | |
|---|---|---|
Market Cap | $21.74B | $3.75B |
Volume | 2,458,317 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $51.84 | $32.90 |
52-Week Low | $32.79 | $7.50 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $35.23B | $2.77B |
Dividend Yield | 4.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smurfit Westrock (SW) trades at $41.45, showing modest daily gains of 0.93% but facing technical bearish signals with 17 sell indicators versus 4 buys. The company reported three consecutive quarterly earnings misses amid cost pressures, though revenue remains stable above $31 billion. Recent strategic moves include the $420 million acquisition of CMPC's Chilean containerboard business to strengthen regional footprint and reduce costs.
Despite unanimous analyst buy ratings and a $71.50 price target suggesting 72% upside, SW faces execution risks from freight cost inflation and margin compression. The stock's high P/E ratio of 44.01 contrasts with weak profitability metrics (ROE 2.74%), creating a divergence between valuation and fundamental performance that warrants cautious optimism.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
